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1. Introduction   
Type 1 diabetes, formerly termed insulin-dependent diabetes mellitus (IDDM), is a chronic 
organ-specific autoimmune disorder thought to be caused by proinflammatory autoreactive 
CD4+ and CD8+ T cells, which mediate progressive and selective damage of insulin-
producing pancreatic beta-cells (Atkinson & Eisenbarth, 2001). The reduction of beta-cell 
mass leads to a lack of insulin and thereby loss of blood glucose control (Boettler & von 
Herrath, 2010).  
The worldwide prevalence of T1D was estimated to be 171 million cases among the adult 
population (Wild et al., 2004). Its annual incidence varies widely from one country to 
another (from less than 1 per 100,000 inhabitants in Asia to approximately up to 25/100,000 
population/year in North America, more than 30 per 100,000 in Scandinavia and up to 
41/100,000 population/year in Europe). It is in steady increase across the globe, especially 
among children aged less than five years (Kajander et al., 2000; Vija et al., 2009). 
According to the European Diabetes (EURODIAB) study group, the prevalence of T1D in 
Europe will increase significantly in children younger than 15 years of age to reach 160,000 
cases in 2020 (Patterson et al., 2009). These data will result in an increasing number of 
patients with longstanding diabetes and with a risk of serious complications (Kessler, 2010). 
These include heart diseases and strokes, high blood pressure, renal failure and ketoacidosis 
(DKA) (Boettler & von Herrath, 2010). 
To date, it has not been possible to prevent the autoimmune response to beta-cells in human, 
due probably to its unknown aetiology, although it is known that development of T1D is 
genetically controlled and thought to be initiated in susceptible individuals by 
environmental factors such as virus infections (Luo et al., 2010; Mukherjee & DiLorenzo, 
2010; von Herrath, 2009). 
It is now evident that targeted destruction may go undetected for many years, but 
antibodies to various beta-cell antigens can be easily demonstrable in the sera of patients at 
risk before clinical onset (Achenbach et al., 2005). Additionally, some endogenous insulin 
secretion is generally present at the onset of clinical diabetes (Scheen, 2004), during which 
time, immunotherapeutic intervention may be effective (Staeva-Vieira et al., 2007). 
This chapter emphasizes the principal immunological risk markers of T1D and especially 
the role of cell-mediated immune response leading to pancreatic beta-cells destruction, as 
well as the most promising immunotherapeutic approaches for prevention and treatment of 
the disease.   
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2. Autoimmunity of the type 1 diabetes 
The autoimmune nature of T1D is initially affirmed by several arguments that are primarily 
indirect, including the association with other autoimmune diseases (Barker, 2006), such as 
the autoimmune thyroid disease (Hashimoto thyroiditis or Graves disease) (Criswell et al., 
2005; Levin et al., 2004), Addison disease (Barker et al., 2005), myasthenia or Biermer’s 
anemia, and the detection of various autoantibodies (Seyfert-Margolis et al., 2006) and islet 
lymphocytes infiltrates (Bach, 1979).  
2.1 Humoral markers of type 1 diabetes 
Although T1D is primarily mediated by mononuclear cells (Carel et al., 1999), diagnosis 
means of the preclinical period  are primarily markers of humoral immune response that are 
represented, for instance, by antibodies to beta-cell antigens, including glutamic acid 
decarboxylase 65, insulin, insulinoma-associated protein 2 islet tyrosine phosphatase, islet 
cell cytoplasm and more recently zinc transporter 8 (Luo et al., 2010) (Fig. 1). Studies of 
twins or in subjects with a family history of autoimmune diabetes have shown that these 
markers, when associated in the same subject, confer very high risk of developing diabetes 
within 5 years (Verge et al., 1996). The predictive value increases from less than 5% in the 
absence of antibodies to more than 90% when antibodies to GAD, tyrosine phosphatase IA-2 
and insulin are present (Bingley et al., 1999; Verge et al., 1996). Additionally, taken in 
aggregate, the use of the level of autoantibody can provide additional predictive 
information for the persistence of autoantibodies and development of T1D (Barker et al., 
2004). Moreover, among metabolic risk markers, the loss of first phase insulin response to 
intravenous glucose has the same prediction value with multiple positive antibodies when it 
is associated with one of these autoantibodies (Krischer et al., 2003). Furthermore, the 
predictive value of having multiple autoantibodies can increase significantly by the presence 
of a high-risk genotype, with a positive predictive value of 67% in multiple antibody–
positive DR3/4 individuals, versus 20% in those without DR3/4 (Yamamoto et al., 1998). 
While, high sensitivity and specificity are required for detection of prediabetes in the 
general population where the prevalence is of the order of 0.3% even when genetic 
susceptibility markers are also included (Hermann et al., 2004). 
2.1.1 Islet cell autoantibodies 
These are markers with best predictive value (Bonifacio & Christie, 1997), because of their 
high sensitivity to the pancreatic insulite (Kulmala et al., 1998) and their high specificity for 
T1D (Gorsuch et al., 1981).  
Islet cell autoantibodies (ICAs) have been the first disease-specific autoantibodies to be 
described in patients with T1D (Bottazzo et al., 1974). They appear until ten years before the 
clinical onset of diabetes (Riley et al., 1990). ICA corresponds to a compounding of different 
specificities antibodies, because they can be fixed on all cellular types of antigenic structures 
present in the islet cell cytoplasm (Atkinson & Maclaren, 1993).   
High ICA levels could be a marker of strong autoimmune reaction and accelerated depletion 
of beta-cell function (Zamaklar et al., 2002). In prediabetic subjects, a higher ICA titer is 
associated with a higher risk for T1D development (Mire-Sluis et al., 2000). In newly 
diagnosed type 1 diabetic patients, ICAs are present in 80%, and ICA reactivity often waned 
after diagnosis, with no more than 5% to 10% of patients remaining ICA positive after 10 
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Fig. 1. Natural history of type 1 diabetes. AgPC: antigen-presenting cell; GAD65A: glutamic acid 
decarboxylase 65 autoantibody; IAA: insulin autoantibody; ICA: islet cell autoantibody; ZnT8A: zinc 
transporter 8 autoantibody.  
years (Gilliam et al., 2004). The frequency of the positive ICA is 80% to 100% (Schatz et al., 
1994) of revelation for a 25 years old T1D or less (Elfving et al., 2003). It decreases remotely 
by the primo-decompensation, reaching approximately 3% in related subjects aged of less 
than 20 years (Schatz et al., 1994).  
ICAs are highlighted by indirect immunofluorescence (Borg et al., 2002a; Elfving et al., 2003; 
Perez-Bravo et al., 2001) on sera incubated with human blood group O pancreas (Takahashi 
et al., 1995; Thivolet & Carel, 1996). They can be also detected by complementary-fixing 
antibody (Knip et al., 1994; Montana et al., 1991), since they mainly belong to the IgG1 
subclass antibodies (Bottazzo et al., 1980). The increase in ICAs may indicate the presence of 
other autoantibodies, corresponding to more IgG1subclasses (Dozio et al., 1994). Association 
with other autoantibodies increases the test specificity, with a decrease in sensitivity 
however (Thivolet & Carel, 1996). ICA levels that exceed 80 JDF (Juvenile Diabetes 
Foundation) units at the time of diagnosis despite better beta-cell function are associated 
with short clinical remission (Zamaklar et al., 2002), and include 53% of disease 
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development risk in five years following their revelation (Dozio et al., 1994). Nevertheless, 
the high levels of ICA found in the family relatives do not necessarily lead to T1D 
development (Bingley, 1996). Likewise, the low rates of these antibodies lessen the disease 
risk (Bonifacio et al., 1990). 
2.1.2 Insulin autoantibodies 
It would be important to recall that protective alleles of insulin gene INS VNTR (variable 
number of tandem repeats) are associated with higher levels of INS messenger RNA 
expression in the thymus (Aribi, 2008; Pugliese et al., 1997; Vafiadis et al., 1997). Insulin 
would then be the main antigens engaged in thymic T cell education and immune tolerance 
induction. Therefore, it has been the first diabetes-related autoantigen to be identified 
(Gilliam et al., 2004). 
Insulin autoantibodies (IAAs) are of weak prevalence at the time of diagnosis (Breidert et al., 
1998). Their levels are increased especially in prediabetics (Palmer et al., 1983), but also in 
newly diagnosed type 1 diabetic subjects. Additionally, IAAs could be confused with insulin 
antibodies (IAs) produced following injection of exogenous insulin; therefore, we cannot 
assess the real level of IAAs in treated patients (Gilliam et al., 2004).  
On the other hand, various studies have shown that the elevated IAA frequency and levels 
are observed mainly in young children (Landin-Olsson et al., 1992) and HLA DR4 subjects 
(Achenbach et al., 2004; Savola et al., 1998; Ziegler et al., 1991). Moreover, IAAs could be 
detected in all children who develop diabetes when they are associated with multiple 
autoantibodies. Furthermore, these antibodies confer high risk in T1D relatives (Ziegler et 
al., 1989), essentially in combination with other autoimmune markers (Bingley et al. 1999; 
Thivolet et al., 2002; Winnock et al., 2001). However, the actual frequency of positivity varies 
considerably from one study to another, according to the IAA assay, age at diagnosis, as 
well as the populations studied (Gilliam et al., 2004). 
Interestingly, IAAs do not necessarily reflect beta-cell destruction. Indeed, they have been 
reported to occur in other autoimmune diseases, such as Hashimoto thyroiditis, Addison 
disease, chronic hepatitis, pernicious anemia, systemic lupus erythematosis, and rheumatoid 
arthritis (Di Mario et al., 1990). 
IAAs can be detected by two assay methods, a fluid-phase radioimmunoassay (RIA) and a 
solid-phase enzyme-linked immunosorbent assay (ELISA); however, it has been shown that 
IAAs measured by RIA were more closely linked to T1D development than those measured 
by ELISA (Murayama et al., 2006; Schlosser et al., 2004; Schneider et al., 1976; Wilkin et al., 
1988). 
2.1.3 Glutamic acid decarboxylase autoantibodies 
Of note, a 64kDa islet cell protein was initially isolated by precipitation with autoantibodies 
present in sera of patients with T1D (Baekkeskov et al., 1982). After laborious searches, this 
protein was identified as glutamic acid decarboxylase (GAD) (Baekkeskov et al., 1990); the 
enzyme that synthesizes the gamma-aminobutyric acid neurotransmitter in neurons and 
pancreatic beta-cells (Dirkx et al., 1995). At that time, GAD autoantibodies had been 
demonstrated to have a common identity in patients with stiff-man syndrome (SMS) and T1D 
(Baekkeskov et al., 1990; Solimena et al., 1988). During the same period, GAD complementary 
deoxyribonucleic acid (GAD cDNA) cloning demonstrate that there are two different genes of 
GAD, designated GAD1 and GAD2 (Bu et al., 1992; Erlander et al., 1991; Karlsen et al., 1991), 
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located on  chromosome 2q31.1  and chromosome 10p11.23, respectively (Bennett et al., 2005). 
GAD1 mRNA has been reported to be translated into GAD67, which is not detected in human 
islets (Karlsen et al., 1991), but is predominantly found in mouse islets (Petersen et al., 1993; 
Velloso et al., 1994). The mRNA for GAD2 gene encodes the GAD65kDa isoform that is 
expressed in human pancreatic islets and brain (Gilliam et al., 2004). 
GAD65 autoantibodies (GAD65A) are revealed in 70% to 80% of cases among prediabetic 
subjects and newly diagnosed patients (Kulmala et al., 1998). They are considered as a good 
retrospective marker of the autoimmune progression, because of their persistence in the sera of 
patients with T1D for many years following diagnosis (Borg et al., 2002b). Whereas, these 
antibodies have a low positive predictive value for beta-cell failure (47%) compared to ICAs 
(74%) (Borg et al., 2001) and can be revealed in patients with neurological disorders, including 
those with gamma-aminobutyric acid (GABA)-ergic alterations (Piquer et al., 2005; Solimena et 
al., 1990). Similarly, they can be present in patients who have other autoimmune diseases 
(Davenport et al., 1998; Nemni et al., 1994; Tree et al., 2000) as well as in patients with type 2 
diabetes (Hagopian et al., 1993; Tuomi et al., 1993). Consequently, they don’t seem to be 
specific to pancreatic beta-cells destruction (Wie et al., 2004; Costa et al., 2002).  
GADAs are usually detected by radioligand-binding assay, which is reported to have higher 
sensitivity, specificity, and reproducibility than other methods using ELISA, enzymatic 
immunoprecipitation, and immunofluorescence assays (Damanhouri et al., 2005; Knowles et 
al., 2002; Kobayashi et al., 2003). 
2.1.4 Anti-tyrosin phosphatase autoantibodies 
These antibodies are directed against two digestion fragments (Jun & Yoon, 1994; Maugendre 
et al., 1997) resulting from trypsin hydrolysis of transmembrane protein expressed in islets and 
the brain, and are present in two related forms with distinct molecular weights, 40kDa and 
37kDa (Bonifacio et al., 1995a; Li et al., 1997; Yamada et al., 1997).  
Of note, the 40kDa antigen is the receptor tyrosine phosphatase-like protein IA-2 associated 
with the insulin secretory granules of pancreatic beta-cells (Trajkovski et al., 2004), also 
called islet cell autoantigen 512 (ICA512)/IA-2 (Bonifacio et al., 1995b; Payton et al., 1995). 
The 37kDa antigen is a tryptic fragment related protein tyrosine phosphatase, designated 
IA-2┚/phogrin (Kawasaki & Eisenbarth, 2002), or islet cell autoantigen-related protein 
tyrosine phosphatase (IAR) (Lu et al., 1996).  
It has been shown that antibodies to the two antigens have similar sensitivity; however, 
epitope mapping studies have suggested that antibodies to IA-2 (IA-2A, insulinoma-
associated protein 2 islet tyrosine phosphatase) appear to be more important for the 
pathogenesis of T1D than those to IA-2┚ (Savola, 2000; Schmidli et al., 1998).  In fact, the 
binding of phogrin autoantibodies could be totally blocked if adding ICA512 to sera positive 
for both ICA512 and phogrin, while the binding of ICA512 antibodies cannot be fully 
blocked with phogrin (Savola, 2000).  
IA-2As can be evaluated by radioligand-binding assay and ELISA (Bonifacio et al., 2001; 
Chen et al., 2005a; Kotani et al., 2002); whereas, RIAs performed much better than ELISAs, 
as was found for GAD65A assays (Verge et al., 1998).  
2.1.5 Zinc transporter 8 autoantibodies 
The human beta-cell-specific zinc transporter Slc30A8 (ZnT8) is a member of the large cation 
efflux family of which at least seven are expressed in islets (Chimienti et al., 2004). It has 
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been recently defined as a major target of humoral autoimmunity in human T1D based on a 
bioinformatics analysis (Dang et al., 2011; Wenzlau et al., 2009). Autoantibodies to ZnT8 
(ZnT8A) have been therefore detected in high prevalence in newly diagnosed type 1 diabetic 
patients (Yang et al., 2010) and obviously overlap with GADA, IA2A, and IAA (Wenzlau et 
al., 2007).  
Of note, ZnT8 autoimmunity could be an independent marker of T1D, given that ZnT8As 
can be present in antibody-negative individuals and in type 2 diabetes, and in patients with 
other autoimmune disorders (Wenzlau et al., 2008).  
Antibodies to ZnT8 can be measured by radioimmunoprecipitation assay using 35S labelled 
methionine in vitro translation products of different fragments of human ZnT8 (Lampasona 
et al., 2010). 
2.2 Immunological anomalies of type 1 diabetes and cellular autoimmunity 
In reality, our understanding of the exact cellular immune mechanisms that lead to the 
development of T1D is limited, and it is possible that the potential target autoantigens may 
be less well defined and more diverse, probably because of the epitopes diversification. 
The immune reaction against beta-cells is due primarily to a deficit in the establishment of 
central thymic tolerance and the activation of potentially dangerous autoreactive T cells and 
B cells that recognize islet antigens. Additionally, aggression of the beta-cells may be 
initiated by other cells and components of the innate immune system. In fact, it has been 
observed that the immune cells peripheral infiltration of the Langerhans islets, a process 
termed perished-insulitis, begins initially with the monocytes/macrophages and dendritic 
cells (DCs) (Rothe et al., 2001; Yoon et al., 2005; Yoon et al., 2001). Upon exposure to 
antigens, islet-resident antigen presenting cells, likely DCs, undergo maturation, leading to 
the expression of cell surface markers that are subsequently required for T cell activation in 
the pancreatic lymph nodes (panLN). CD4+ T cells and macrophages home to islets and 
release pro-inflammatory cytokines and other death signals that acutely trigger necrotic and 
pro-apoptotic pathways (Fig. 2). 
2.2.1 T cells and B cells 
Although both humoral and cell-mediated immune mechanisms are active during T1D, 
CD4+ and CD8+ T cells recognizing islet autoantigens are the main actors of beta-cells death 
(DiLorenzo et al., 2007; Gianani & Eisenbarth, 2005; Toma et al., 2005). B cells may play a 
role in inducing inflammation and presentation of self-antigen to diabetogenic CD4+ T cells 
(Silveira et al., 2007). 
It has been repeatedly observed that the pancreatic islets of diabetic patients prior to and at 
diagnosis are infiltrated by T lymphocytes of both CD4 and CD8 subsets (Hanninen et al., 
1992; Imagawa et al., 2001; Kent et al., 2005). Additionally, their circulating number among 
type 1 diabetic patients is higher than those of B cells (Martin et al., 2001). Moreover, the 
disease can be transferred to NOD-scid mice that are genetically deficient in lymphocytes 
(Christianson et al., 1993; Sainio-Pollanen et al., 1999; Yamada et al., 2003), or to newborn 
NOD mice exposed to atomic radiation (Miller et al., 1988; Yagui et al., 1992) by injection of 
T CD4+ and CD8+ spleenocytes from prediabetics. However, injection of anti-islets 
antibodies does not induce autoimmunity (Timist, 1996) and beta-cell damage may develop 
in individuals with severe B cells deficiency (Martin et al., 2001).  
www.intechopen.com
 Autoimmunity and Immunotherapy of Type 1 Diabetes 9 
 
Fig. 2. Hypothetical scheme of the autoimmune response of type 1 diabetes: cellular 
interaction and molecules that can be involved within the destruction of pancreatic islets 
beta-cells. (1) Antigen exposure and TCR signalling pathway: AgPC exposes epithopes derived from 
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beta-cells on its membrane surface by some class II MHC molecules that are involved in the 
susceptibility of T1D. The autoantigens/class II MHC complex, adhesion molecules, particularly B7, 
IL-12 derived from AgPC, and possibly other immunogenic signals, could join and cause the 
activation of CD4+ Th0 cells. Many factors (physical, psychological, and chemical stress) are able to 
guide the Th0 differentiation towards Th1 cell. (2.1 and 2.2) Activation of Th1 cells: immunogenic 
signals resulting from class II MHC/peptide-TCR, CD40-CD154 and CD28-B7 interactions induce 
the activation of Th1 cells. (3) Beta-cells destruction: activated Th1 cells produce IL-2, TNF-┚ and 
IFN-┛ cytokines, increasing the activation of islet-infiltrated macrophage and autoreactive cytotoxic 
CD8+ cells. These cells can destroy pancreatic beta cells by proinflammatory cytokines, granzymes 
and perforin, FasL-Fas interaction, and oxygen/nitrogen free radicals. Anomalies of autoreactive T 
cells suppression could be due to the decreased number and/or function of peripheral regulatory cells 
affecting both NK T cells and natural CD4+CD25+/CD25highFoxp3+ T-reg cells. AgPC: antigen-
presenting cell, CD: cluster of differentiation, DC: dendritic cell, Fas/FasL: CD95/CD95 Ligand, 
Foxp3: transcription factor forkhead box P3, IFN: interferon, IL: interleukin, MHC: major 
histocompatibility complex, NK T: natural killer T cell, T1D: type 1 diabetes, TCR: T cell receptor, 
Th: T helper, TNF: tumor necrosis factor.TNF-RI: tumor necrosis factor receptor type I. 
2.2.2 CD4+ and CD8+ T cells and ways of beta-cells destruction 
The precise role of each of these cells in pancreatic islets destruction remains unclear and 
controversial. Therefore, two main pathways may be involved in triggering the disease, both 
of which are activated following recognition of beta-cell autoantigens. 
According to the indirect way, the critical role in T1D development could be attributed to 
autoreactive CD4 T cells, as exemplified by the observation that the major histocompatibility 
complex class II (MHC II) genes are the main candidate genes to which a key role can be 
assigned in the autoimmune process according to their strong association with the disease 
(Aribi, 2008; Concannon et al., 2009). These cells can initiate beta-cells destruction and lead 
to tissue cell damage (Peterson & Haskins, 1996), through the secretion of cytokines with 
toxic effects (Amrani et al., 2000), then recruit T CD8+ lymphocytes (McGregor et al., 2004). 
According to the direct way, autoreactive T CD8+ lymphocytes (Anderson et al., 1999) could 
initiate beta-cells destruction, as shown in transgenic TCR (NOD/AI4ǂǃ Tg) NOD mice, that 
T1D autoimmunity beginning can be achieved in total absence of CD4+ T cells and requires 
only CD8+ T cells (Graser et al., 2000). Additionally, disease development is reduced only 
when adult NOD mice are injected with anti-class I MHC molecules or anti-CD8 mAb 
molecules (Wang et al., 1996). Moreover, ǃ2-microglobulin-deficient (ǃ2m–/–) and anti-CD8 
mAb-treated NOD mice, yet deficient in CD8+ T cells develop neither insulitis nor T1D 
(Yang et al., 2004).  
However, direct evidence for these observations is compelling only in animal models in 
which adoptive transfer experiments are feasible ethically (Di Lorenzo et al., 2007). 
Additionally, several differences can be revealed between men and animal models of T1D. 
For example, in men, immunohistological studies of type 1 diabetic pancreatic-biopsy 
showed a strong number of islet-infiltrated CD8+ cytotoxic T cells compared to that of islet-
infiltrated CD4+ T helper cells (Itoh et al., 1993). In contrast, in NOD mice, pancreatic islets 
are infiltrated predominantly by CD4 + T cells compared to CD8+ T cells (Kida et al., 1998). 
2.2.3 Regulatory T cells/effectors T cells imbalance 
The primary function of Treg cells is the maintenance of self-tolerance in order to prevent 
the development of autoimmune diseases (Sakaguchi et al., 1995). They also have the ability 
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to control a runaway immune response by different feedback mechanisms, involving the 
production of anti-inflammatory cytokines, direct cell-cell contact or modulating the 
activation state of antigen-presenting cells (AgPCs) (Corvaisier-Chiron & Beauvillaina, 
2010). Normal tolerance to self-antigens is an active process that has a central component 
and a peripheral component. Central tolerance implies induction of tolerance in developing 
lymphocyte when they encounter self-antigens that are present in high concentration in the 
thymus or bone marrow; while peripheral tolerance is maintained by mechanisms of self-
reactive T cells elimination by clonal deletion, anergy or ignorance (Wallace et al., 2007). 
Among these three mechanisms only the deletion is induced by Treg cells (Corvaisier-
Chiron & Beauvillaina, 2010).  
Different subpopulations of Treg cells have been identified: natural Treg (nTreg) cells that 
drived from the thymus and migrate to peripheral tissues, and peripherally induced Treg 
(iTreg) (Corvaisier-Chiron & Beauvillaina, 2010). nTreg cells represent 2-4% of circulating 
lymphocytes in humans (Wahlberg et al., 2005) and are characterized by the expression of 
CD4, CD25high, CD127low molecules and high levels of the transcription factor FoxP3 
(forkhead box P3) (Corvaisier-Chiron & Beauvillaina, 2010; Wahlberg et al., 2005). They also 
express surface CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) and GITR (TNF 
receptor family glucocorticoidinduced-related gene) involved in membrane mechanisms of 
Treg suppression (Corvaisier-Chiron & Beauvillaina, 2010). 
Except pathological conditions, there is a balance between regulatory T cells and effector T 
cells. Some genetic and environmental factors might cause deregulation of this balance in 
favor of self-reactive lymphocytes that may induce or predispose to the development of 
autoimmune diseases, including T1D (Brusko et al., 2008).  
In NOD mice and diabetic patients and in several organ-specific animal models of 
autoimmunity as well as in humans (Furtado et al., 2001; Kriegel et al., 2004; Kukreja et al., 
2002), it has been demonstrated that  number and/or function of peripheral regulatory cells 
affecting both nTreg cells (CD4+CD25+Foxp3+) (Fontenot et al., 2003; Hori et al., 2003; 
Khattri al., 2003) and natural killer (NK) T cells (Duarte et al., 2004; Hong et al., 2001) are 
decreased; while self-reactive peripheral T cells number is increased (Berzins et al., 2003). 
Additionally, decreased contacts between effectors and nT-reg cells seem to belong to 
additional events leading to autoreactive T cells activation and proliferation (Lindley et al., 
2005; Maloy & Powrie, 2001; Piccirillo et al., 2005). 
On the other hand, various studies showed that T1D in both humans and NOD mice could 
be due to the weak secretion of IL-4 resulting from a deficiency in NK T cells (Lehuen et al., 
1998; Wilson et al., 1999) and that diabetes can be prevented in mice by transfer of NK T 
cell–enriched CD4–CD8– double negative cells (Baxter et al., 1997; Falcone et al., 1999; 
Lehuen et al., 1998) or of thymic-derived nT-reg cells (Chen et al., 2005b; Lindley et al., 2005; 
Luo et al., 2007).  
2.2.4 Regulatory T cells/Th17 cells imbalance 
Th17 cells represent a subtype of T cells that can be generated in the presence of IL-23 even 
from cells deficient in transcription factors required for Th1 (T-bet) or Th2 (GATA-3) cells 
development (Harrington et al., 2005; Park et al., 2005). However, IL-23 would not be a 
factor for Th17 cells differentiation but rather intervene in their survival and proliferation. In 
fact, naive T cells do not express receptors for IL-23 and do not differentiate into Th17 cells 
only in the presence of IL-23 (Mangan et al., 2006). Additionally, Th17 cells express a specific 
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transcription factor, RORC2 (retinoic acid receptor-related orphan receptor C2, known as 
RORǄt in mice), which is crucial for the generation of Th17 cells, especially via the 
transcriptional induction of the gene encoding IL-17 and the expression of IL-23 receptor 
(Ivanov et al., 2006). To acquire a full differentiation of such cells, RORC2 acts in cooperation 
with other transcription factors, including RORǂ, STAT3, IRF-4 and Runx1 (Miossec et al., 
2009).  
The discovery of factors involved in the differentiation of Th17 and Treg cells suggests the 
existence of Treg/Th17 balance, controlled by IL-6 (Kimura et al., 2011). More recently, 
increased Th17 immune responses  or imbalance of nTreg cells and IL-17 producing Th17 
have been found to be associated to the onset of the disease in both humans and NOD mice 
or Diabetes-prone BioBreeding (DP-BB) rats (Honkanen et al., 2010; Shi et al., 2009; van den 
Brandt et al., 2010). While, these observations should be confirmed further. 
2.2.5 Th1/Th2 imbalance  
Different factors, including physical, psychological, and chemical stress (Ernerudh et al., 
2004) can produce imbalance in the proportions of CD4+ Th1 cell and CD4+ Th2 cell subsets 
(Eizirik et al., 2001; Rabinovitch et al., 1994; Thorvaldson et al., 2005). Several studies have 
shown that the autoimmune aggression leading to T1D involves Th1 cells (Kida et al., 1999; 
Sharif et al., 2002; Yoon & Jun, 2005). However, Th2 cells seem to be associated with 
protection against beta-cells destruction (Cameron et al., 1997; Ko et al., 2001; Suarez-Pinzon 
& Rabinovitch, 2001).  
In NOD mouse model, T1D can be transferred among animals through the injection of Th1 
cells (Kukreja et al., 2002). T1D-sex relationship has been linked to the type of produced 
cytokines. Lymphocytes infiltrating female mice pancreatic islets produce high levels of Th1 
cytokine mRNA and low levels of Th2 cytokine mRNA. On the other hand, male mice are 
more resistant to T1D because they produce more Th2 cytokine mRNA and less cytokine 
Th1 mRNA (Azar et al., 1999; Fox & Danska, 1997). Likewise, young NOD mice spleenocytes 
expressing CD62L and CD25, i.e. CD4+CD45RBlow (memory/activated cells) which are 
involved in dominant protection against T1D development, show an overproduction of Th2 
cytokines, yet tend towards an overproduction of Th1 cytokines right before diabetes onset 
(Shimada et al., 1996). Besides, female NOD mice have more spleenocytes CD45RBlow CD4+ 
and more spleenocytes CD4+CD25+ activated helper cells than do male NOD mice have 
(Azar et al., 1999). Moreover, it is possible to prevent T1D in NOD mice with a single 
injection of insulin or GAD peptide (Han et al., 2005), because it causes a reduction in levels 
of Th1 cytokines and an increase in the ones of Th2 cytokines (Muir et al., 1995; Sai et al., 
1996). 
2.2.6 Innate immunity 
It has been recently observed that innate immunity may play a critical role in the development 
of T1D. This observation has been supported by works showing that infusions of alpha-1 
antitrypsin, a serine protease inhibitor that protects tissues from enzymes produced from 
inflammatory cells, were found to reverse new-onset diabetes in NOD mice (Koulmanda et al., 
2008). Many effects have been described, including reduced insulitis, enhanced beta-cell 
regeneration, and improvement in peripheral insulin sensitivity (Luo et al., 2010). 
Thanks to many experiments conducted in animal models, it has been shown that toll-like 
receptors (TLRs), as part of the innate immune system, may have an important role in T1D 
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development (Filippi & von Herrath, 2010). For example, injection of low dose of TLR-3 
stimulus poly I:C has been shown to prevent diabetes in the disease-prone Biobreeding rat 
model (Sobel et al., 1998). In addition, TLR deficiency has been associated with decreased 
number of some Treg. Indeed, T cells with a regulatory phenotype can express TLR-2, TLR-
4, TLR-5, TLR-7 and TLR-8 (Caramalho et al., 2003; Sutmuller et al., 2006), and the 
proliferation of Treg cells has been observed especially following the administration of TLR-
2 ligands to TLR-2-deficient mice (Sutmuller et al., 2006). Moreover, it has been suggested 
that protection against T1D in NOD mice through infection with Lymphocytic 
Choriomeningitis Virus (LCMV) is dependent on the emergence of Tregs and TLR-2 
(Boettler & von Herrath, 2011). 
2.2.7 Macrophages 
Macrophages play a significant role in the oxidative stress (Ishii et al., 1999; Rozenberg et al., 
2003), innate immunity (Bedoui et al., 2005; Lawrence et al., 2005) and inflammation (Ishii et 
al., 1999; Lawrence et al., 2005). Macrophages and other AgPCs in the panLN (Pearl-Yafe et 
al., 2007) initiate T cell sensitization, and concomitantly activate regulatory mechanisms 
(Kaminitz et al., 2007). The central role of macrophages in the cellular immune response 
(Durum et al., 1985) and in the development and activation of beta-cell-cytotoxic T cells 
during T1D (Yoon & Jun, 2001) has been previously proven in BioBreeding (BB) rats where a 
macrophage insulitis preceding lymphocyte insulitis could be prevented by a silica 
intraperitoneal injection (Albina et al., 1991). However, macrophages are also able to exert a 
suppressor effect on lymphocyte proliferation (Albina et al., 1991; Taylor et al., 1998; Zhang 
& McMurray, 1998). This effect is exerted on T and B cells alike and is mediated by several 
ways involving especially prostaglandins and nitric oxide as metabolic mediators (Albina et 
al., 1991; Ding et al., 1988; Jiang et al., 1992).  
A mechanism by which macrophages intervene preferentially in Th1 and Th2 clones 
differentiation has been suggested. Hence, macrophages can interact with Th cells and 
induce polarization toward the Th1 or Th2 cell subset depending on the oxidation level of 
their glutathione content. With low levels of oxidized glutathione, they induce a 
polarization toward Th1 phenotype, whereas high levels of oxidized glutathione lead to Th2 
differentiation (Murata et al., 2002). Additionally, some IL-12 antigenic stimulations induce 
Th1 cells activation (Hsieh et al., 1993). Th2 cells activation goes through the action of IL-4 
and IL-10, which can also be produced by activated macrophages in the presence of immune 
complexes (Fiorentino et al., 1991). 
2.2.8 Dendritic cells 
DCs play an important role in initiating the immune response and antigen presentation, as 
well as in maintaining peripheral self-tolerance (Steinman et al., 2003). There are mostly 
immature DCs (iDCs), which have poor antigen presentation functions (de Vries et al., 
2003), may be involved in immunoregulatory functions in autoimmune processes (Dorman 
et al., 1997). These functions depend largely on co-stimulation during the maturation 
process. Thus, tolerogenic DCs are iDCs with reduced allostimulatory capacities and low 
expression levels of costimulatory molecules, like CD40, CD80 and CD86 molecules. 
However, the transition to the mature state, following exposure to pathogens, leads to 
increased antigen presentation and expression of T cell co-stimulatory molecules and T cell 
responses (Steinman & Banchereau, 2007). 
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Nevertheless, the acquisition of a high degree of maturity and expression of adhesion 
molecules, especially CD86 molecule, allows the DCs to provoke the activation of 
CD4+CD25+ regulatory T cells capable of inhibiting autoimmune disease (Yamazaki et al., 
2003). It is therefore quite possible that the DCs involved in triggering the autoimmune 
process leading to T1D (Clare-Salzler et al., 1992; Feutren et al., 1986; Mathis et al., 2001), are 
mature cells with a large capacity for antigen presentation, but without effect on regulatory 
T cells. 
Additionally, it has been shown that DCs are the initiators of the islet infiltration in NOD 
mice (DiLorenzo et al., 2007). Such cells isolated from the panLN could prevent diabetes 
development when transferred adoptively to young recipients (Bekris et al., 2005), while 
those from other sites could not, suggesting that the activation of autoreactive T cells occurs 
at this site and that their suppression would be due to deletion or regulation mechanisms 
(Belz et al., 2002; Hugues et al., 2002). 
2.2.9 Adhesion and costimulation molecules and cell signaling 
T-cell-receptor (TCR)-mediated recognition of pancreatic autoantigens is a central step in the 
diabetes pathogenesis (Bach, 2002). Interaction between TCR and pancreatic peptides 
aberrantly complexed with class II MHC molecules on pancreatic beta-cells (Foulis, 1996) or 
expressed on the AgPCs in panLN is required for the activation of Th1 lymphocytes. 
Similarly, TCR interaction with autoantigen peptides presented by class I MHC molecules 
on pancreatic beta-cells is essential for the activation of cytotoxic CD8+ autoreactive T 
lymphocytes in pancreatic islet. Activated Th1 cells induce positive signals involving IL-2, 
TNF-ǃ and IFN-Ǆ cytokines to increase the activation of islet-infiltrated macrophage and 
cytotoxic CD8+ cells. 
Beta-cells aggression can be mediated by proinflammatory cytokine-mediated cell killing 
(IL-1 (Aribi et al., 2007; Sparre et al., 2005), TNF-ǂ (Christen et al., 2001; Lee et al., 2005), 
TNF-ǃ, IFN-Ǆ, IL-18 (Nakanishi et al., 2001; Szeszko et al., 2006), IL-12 (Giulietti et al., 2004; 
Holtz et al., 2001), IL-6 (Kristiansen & Mandrup-Poulsen, 2005; Targher et al., 2001), and IL-8 
(Erbağci et al., 2001; Lo et al., 2004), etc.), granzymes (GRZ) and perforin (PRF1), FasL-Fas 
(CD95L-CD95) interactions, hydrogen peroxide and free radicals (Mukherjee & DiLorenzo, 
2010). 
Numerous adhesion molecules and signalling proteins, can amplify activation of the 
CD3/TCR complex leading to self-reactive T cells proliferation within panLN. Experimental 
NOD mice studies highlighted three principal costimulation pathways for such activation: 
CD28-B7, CD40-CD40L (CD 154) (Bour-Jordan et al., 2004) and NKG2D-RAE-1 (von 
Boehmer, 2004). Therefore, it has been previously shown that the T1D occurrence is 
decreased by injection of anti-B7.2 mAb’s (Lenschow et al., 1995). Meanwhile, invalidation 
of B7.2 (CD86) (NOD/B7.2–/–) confers protection against the disease (Salomon et al., 2001). 
Additionally, ablation of CD40-CD40L pathway with neutralizing antibodies (anti-CD40L 
mAb’s) or with invalidation of CD40L (NOD/B7.2–/–) prevents the early stages of T cell 
activation in the panLN (Green et al., 2000). Moreover, it has been demonstrated that the 
activated islet-infiltrated CD8+ T cells express NKG2D molecules and that the treatment of 
NOD mice with anti-NKG2D mAb’s can prevent T1D development (Ogasawara et al., 2004). 
2.2.10 Vitamin D status 
The gradual increase in the frequency of T1D from the Equator to the Poles, especially 
among children born in spring or early summer and in the winter months has been 
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interpreted as the consequence of limited exposure to sun and low vitamin D status. 
Additionally, case-control studies have consistently demonstrated an association between 
the incidence of T1D and vitamin D status in children and pregnant women, and an inverse 
relationship between vitamin D intake from diet and supplements and seasonal variations 
in the incidence of T1D (Pittas & Dawson-Hughes, 2010). 
Experimental data could also confront the observation about the relationship between 
vitamin D and T1D. Indeed, the insulin-producing beta-cells, as well as other cell types of 
the immune system (Stoffels et al., 2006), express the vitamin D receptor (VDR) and 1-
alpha-hydroxylase enzyme (Nikalji & Bargman, 2011). By regulating the extracellular 
calcium concentration and transmembrane calcium fluxes, vitamin D may extend to 
preservation of insulin secretion and insulin sensitivity. Besides, vitamin D has 
immunomodulatory properties and is able to affect the autoimmune process leading to 
T1D (Bobryshev, 2010). 
3. Immunotherapy of type 1 diabetes 
Intervention and prevention strategies currently under consideration for T1D aim to reverse 
immune autoreactivity and restore beta-cell mass (Boettler & von Herrath, 2010; Bougneres 
et al., 1988). Immunotherapy can be used to induce immunological tolerance to beta-cell 
antigens using various protocols (Haase et al., 2010), involving both islets antigen-non-
specific and antigen-specific approaches, but so far success has been limited.  
Immunomodulation strategies have been generally achieved in two stages of the disease: 
prior to clinical onset but after the appearance of islet autoantibodies (secondary prevention) 
and immediately after diagnosis (intervention) (Staeva-Vieira et al., 2007) (Fig. 3). Based on 
the preclinical and clinical outcomes of studies using these therapies, combination with islet  
 
 
Fig. 3. Stages of type 1 diabetes prevention: objectives and selective targeting. 
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transplantation or stem cells for beta-cell regeneration are required in order to re-establish 
peripheral tolerance and to achieve a lasting remission (Marin-Gallen et al., 2010). 
Nevertheless, it is important to select eligible patients for such therapy, both to avoid 
toxicity and improve the chances of successful treatment (June & Blazar, 2006). 
3.1 Non-antigen-specific immunotherapeutic approach for type 1 diabetes 
For non-antigen-specific immunomodulation approch, many protocols using chemical- and 
antibody-mediated therapies have shown promise to the effects of various 
immunosuppressive drugs, including cyclosporine A (CsA), corticoïdes, azathioprine, T cell 
modulators (anti-CD3, anti-thymocyte globulin (ATG)), B cell-depleting agents (Rituximab: 
anti-CD20), anti-inflammatory molecules (anti-interleukin (IL)-1, anti-tumour necrosis factor 
(TNF)-ǂ and anti-TNF-Ǆ), cytokine-receptor-directed therapies and small-molecule protease 
inhibitors (Boettler & von Herrath, 2011; Luo et al., 2010; Sia, 2005; Silverstein et al., 1988) 
(Table 1). However, we have to acknowledge that these drugs increase the risk of 
developing infections and malignancies, favor the occurrence of metabolic complications 
such as dyslipidemia and hypertension and that some of them have been shown to inhibit 
beta-cell regeneration (Nir et al., 2007; Vantyghem et al., 2009). In addition to the 
immunosuppressant toxicity, recurrence or persistence of the autoimmune process has been 
observed after withdrawal of the immunosuppressive agents.  
Immunomodulation therapies with nicotinamide and Bacillus Calmette-Guérin (BCG) have 
been tested in many clinical T1D prevention trials, but they showed no advantageous effects 
(Huppmann et al., 2005). Despite these negative results, large placebo-controlled clinical 
trials continue to illustrate the efficacy of these drugs in preventing T1D in newly diagnosed 
patients or in first-degree relatives of subjects with the disease. 
Other immunomodulatory drugs that directly target immune cells have also been tested 
with success, especially in animal models of T1D, but some of them have run into major 
difficulties. They include DCs-based therapy, mainly the endocytic receptor involved in 
antigen processing and presentation DCs (DEC-205 (Ly75/CD205)), drugs targeting T 
cells (CTLA4-Ig:  anti-CD4, anti-CD45) (Staeva-Vieira et al., 2007; Gregori et al., 2005), 
AgPCs (antibodies to CD40L or CD40) and NK T cells (alpha-galactosyl-ceramide (ǂ-Gal-
Cer), etc. (Chen et al., 2005c; Hong et al., 2001; Rewers & Gottlieb, 2009). 
Although most of the immunomodulator treatments induce Treg cells activation, the direct 
infusion of ex vivo-expanded regulatory T cells has been considered to be a potential to 
prevent T1D (Lundsgaard et al., 2005; Tang et al., 2004; Tarbell et al., 2004) as well as other 
diseases, such as systemic lupus erythematosus (SLE) (Zheng et al., 2004), multiple sclerosis 
(MS) (Kohm et al., 2002) and inflammatory bowel disease (IBD) (Mottet et al., 2003). Treg-
based cell therapy must meet at least four important therapeutic criteria: to (1) avoid the 
induction of immunogenicity of the infused cells; (2) prevent or delay cellular 
immunosenescence; (3) maximize help; and (4) be cognizant of the known differences 
between mouse and human T-cell biology (June & Blazar, 2006).  
Moreover, drugs targeting adhesion molecules, such as Alefacept (antibody to leucocyte 
function-associated antigen-3 (LFA-3)), Efalizumab (antibody to LFA-1), FTY720 
(immunosuppressive drug inhibiting activated T cell extravasation and trafficking to sites of 
inflammation),  show promise in a significant proportion of patients with other diseases and 
are therefore of high potential interest for testing in T1D (Staeva-Vieira et al., 2007). 
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Therapeutic agent 
Methodof 
delivery 
Phase 
Population 
targeted 
ClinicalTrials.gov identifier 
Otelixizumab SC III ND 
NCT00946257 
NCT00451321 NCT00678886 
NCT01123083 
Teplizumab IV, SC I/II ND 
NCT01030861 
NCT00378508 
NCT00870818 NCT00806572 
INGAP peptide SC II EP 
NCT00995540 
NCT00071409 
Peptide-MHC class II 
dimmers 
PRT // // No trials on humans 
CsA O PS ND NCT/URL links no longer available 
Nicotinamide O ES SR NCT/URL links no longer available 
Atorvastatin O I ND NCT00974740 
BCG ID I ND NCT00607230 
Gluten-free diet O OG NR NCT01115621 NCT00279318 
DHA O II CR NCT00333554 
BP/Hyd. casein O II CR 
NCT01055080 
NCT00607230 
Vitamin D3 O I NR NCT00141986 
Diazoxide O IV ND NCT00131755 
hrIFN-α O II ND NCT00024518 
hrIL-1Ra SC III ND 
NCT00711503 
NCT00645840 
Canakinumab SC II ND NCT00947427 
AAT O I ND NCT01319331 
Rituximab IV III ND NCT00279305 
Alemtuzumab IV I ND NCT00214214 
ATG IV II ND NCT00515099 
CTLA4-Ig IV II ND NCT00505375 
Auto UCB INF II EP NCT00305344 
Auto ODN DC INF I EP NCT00445913 
Prochymal IV II ND NCT00690066 
Table 1. Non-antigen-specific tolerance-based clinical trials for type 1 diabetes. AAT: alpha 1-
antitrypsin (Aralast NP); Alemtuzumab: anti-CD52 monoclonal antibody (Campath 1H®); ATG: 
anti-thymocyte globulin; Auto ODN DC: autologous  dendritic cells treated ex vivo with the mixture 
of the antisense oligodeoxynucleotides; Auto UCB: autologous umbilical cord blood; BCG: Bacillus 
Calmette-Guérin; BP/Hyd. casein: bovine protein (cow’s milk) or hydrolyzed casein formula; 
Canakinumab: human anti-interleukin-1┚ monoclonal antibody; CR: children at risk of T1D; 
CTLA4-Ig: cytotoxic T lymphocyte antigen-4 immunoglobulin (Abatacept); DHA: docosahexaenoic 
acid (omega-3 fatty acid supplementation diet);  EP: established patients; ES: efficacy studies; hrIFN-
┙: human recombinant interferon-┙ (Roferon, Roche); hrIL-1Ra: human recombinant interleukin-1 
receptor antagonist (Anakinra [Kineret®]); ID: intradermal; INF: infusion; INGAP: islet neogenesis 
associated protein (15 amino-acid sequence in INGAP peptide, Exsulin); CsA: cyclosporin A; IV: 
intravenously; ND: newly diagnosed; NR: newborns at risk of T1D; O: oral; OG: ongoing; 
Otelixizumab: ChAglyCD3 (aglycosylated human anti-CD3 monoclonal antibody, TRX4); 
Prochymal: mesenchymal stem cells; PRT: parenteral vaccination; PS: pilot studies; Rituximab: anti-
CD20 monoclonal antibody; SC: subcutaneously; SR: subjects at risk of T1D; Teplizumab: hOKT3┛ 1 
(ala-ala) (mutated human anti-CD3 monoclonal antibody). 
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3.2 Antigen-specific tolerance strategies for type 1 diabetes 
The interest in induction of antigen-specific tolerance to beta-cell antigens for immune 
prevention of T1D development increased due to the lack of mild non-antigen-specific 
immunosuppressive agents. This therapeutic approach improves remarkable longevity and 
long term health in T1D patients and allows most of them to escape the major degenerative 
complications (Bach, 2003). It can occur as a result of clonal anergy and deletion of antigen-
specific autoreactive T cells or induction of regulatory cells and immune deviation 
(Peakman & Dayan, 2001). 
Paradoxically, the induction of tolerance may not be limited to the immune response against 
the injected antigen, but could be extended to responses against other antigens by a close 
proximity mechanism involving immunosuppressive cytokines (Bach, 2003). Therefore, the 
administration of the antigenic epitope specifically recognized by receptors on autoreactive 
T cells as part of the beta-cells would be more attractive than the whole antigen 
administration, given the higher levels of its specificity, but also the relatively modest costs 
of its synthesis (Atassi & Casali, 2008) (Fig. 4). 
Different antigen-specific therapeutic approaches have shown efficacy in mouse models of 
T1D and have been studied most intensively in terms of inducing tolerance in humans 
(Boettler & von Herrath, 2010). They mainly include administration of immunogenic epitope 
peptide or whole protein from islet autoantigen, through parenteral, oral and nasal routes. 
Most of these approaches have been translated into clinic, but none of them have shown 
convincing promise in recent-onset T1D so far.  
The most important clinical trials that have been reported with particular interest have 
focused on oral administration of parenteral and oral insulin clinical trials, efficacy and 
safety study on subcutaneous administration of heat-shock protein peptide (hsp60), 
DiaPep277, in C-peptide positive type 1 diabetes patients and safety experience on 
subcutaneous injection with the 65kDa isoform of glutamic acid decarboxylase in alum 
(GAD-alum) and an altered peptide ligand based on putative major autoantigenic sites in 
the insulin B9-23 chain, which had induced strong Th2 responses in animal models (Alleva 
et al., 2006; Alleva et al., 2002;  Thrower & Bingley, 2009) (Table 2).  
It has been observed in the Diabetes Prevention trial – Type1 (DPT-1) that oral 
administration of insulin in a group of patients with high IAA titers might allow an 
important delay in T1D onset (Skyler et al., 2005). TrialNet is now testing the efficacy of oral 
insulin in decreasing the chances of high-risk individuals converting to T1D (Haller et al., 
2007). The immunomodulation with hsp60 has shown to provide some preservation of C-
peptide in newly diagnosed adult type 1 diabetics and a significant reduction in 
inflammation of the pancreas with continued insulin production, suggesting that the 
progression of the disease may be prevented (Elias et al., 2006; Lazar et al., 2007; Raz et al., 
2001). Additionally, the safety experience with subcutaneous GAD65 (Diamyd’s GAD65) 
has been demonstrated in latent autoimmune diabetes of adulthood (LADA) patients 
(Agardh et al., 2005). The results indicate that this treatment increases fasting p-C-peptide 
concentrations after 24 weeks in subjects treated with a moderate dose (20 μg) but not in 
subjects treated with higher doses (100 or 500 μg) or lower doses (4 μg) (Stenström et al., 
2005).  
Other trials using a DNA vaccine-based approaches include BHT-3021 (Bayhill 
Therapeutics) (Burn, 2010), a plasmid encoding proinsulin, designed to target specific 
pathogenic immune cells. BHT-3021 has shown considerable effectiveness in the new-onset 
 
www.intechopen.com
 Autoimmunity and Immunotherapy of Type 1 Diabetes 19 
 
 
 
Fig. 4. CD4 and CD8 T cell epitopes for human pancreatic beta-cell antigens. (Amino acid 
positions are indicated in brackets.) 
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diabetes in the NOD mice.  In the current phase I/II clinical trial, BHT-3021, administered 
by intra-muscular route, demonstrated preservation of C-peptide and an acceptable safety 
and tolerance in patients with T1D (Sanjeevi, 2009). 
 
Therapeutic agent 
Methodof 
delivery 
Phase 
Population 
targeted 
ClinicalTrials.gov 
identifier 
Insulin 
O III RR NCT00004984 
IN III CR NCT00223613 
NCT00336674 
PRT II RR NCT00654121 
IBC-VS01 IM I ND NCT00057499 
NBI-6024 SC I ND NCT00873561 
BHT-3021 IM I EP NCT00453375 
rhGAD-alum SC II ND NCT00529399 NCT01129232 
DiaPep277 SC III ND 
NCT01103284 
NCT00615264 
NCT00644501 
Table 2. Antigen-specific tolerance-based clinical trials for type 1 diabetes. CR: children at risk 
of T1D; EP: established patients; DiaPep277: Hsp60 immunodominant peptide p277; IBC-VS01: 
human insulin B chain in incomplete Freund's adjuvant (IFA) vaccine; IM: intramuscular; IN: 
intranasal; NBI-6024: altered peptide ligand (APL) insulin B9-23; ND: newly diagnosed; PRT: 
parenteral; rhGAD-alum: recombinant human glutamic acid decarboxylase (rhGAD65) formulated 
in alum; RR: relatives at risk of T1D; SC: subcutaneously; SR: subjects at risk of T1D. 
3.3 Combination immunotherapy approaches 
Failure to induce a lasting complete remission in patients with T1D using any single agent 
suggests that combination therapies may be needed for effective prevention of the disease or 
reversal of new-onset T1D (Luo et al., 2010). Among these approaches that are currently 
being tried, combinations between immunosuppressive or anti-inflammatory and antigen-
specific vaccines are of particular interest, because of their quite promising early preclinical 
trial results. The most potent and promising ones were schemes based on a combination of 
anti-CD3 treatment with GAD-alum, intranasal proinsulin peptide (Bresson et al., 2006), 
proinsulin DNA (BHT-3021), oral insulin or anti-inflammatory drugs (Matthews et al., 2010) 
(Fig. 5). 
4. Conclusions 
T1D results from selective autoimmune destruction of insulin-producing pancreatic islet 
beta-cells.  
Although the cause of the disease is still not fully understood, multiple immune 
abnormalities, involving dysfunctional regulation of the immune system that leads to the 
activation of self-reactive CD4+ and CD8+ T cells as well as DCs and macrophages, are 
believed to be a major component behind beta-cells destruction.  
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Fig. 5. Main combination immunotherapies for type 1 diabetes. A1AT: alpha 1-antitrypsin; 
Anakinra: IL-1RA (Amgen); ATG: anti-thymocyte globulin; ATNFA: anti-tumor necrosis factor 
alpha; BHT-3021: proinsulin deoxyribonucleic acid; CTB-INS plasmid: cholera toxin B chain 
insulin; DZB: daclizumab (anti-CD25 monoclonal antibody); GAD-ALUM: glutamic acid 
decarboxylase formulated in Alum (Diamyd); GLP1: glucagon-like peptide-1; MMF: 
mycophenolate mofetil; PGCSF: pegylated granulocyte colony stimulating factor; PRO-IP: 
proinsulin peptide ; Rilonacept: IL-1 Trap. 
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Given that there is evidence that the inflammatory phase preceding the destruction of beta-
cells may be reversible and that humoral markers of the autoimmunity are usually present 
many years prior to and at the time of diagnosis, various approaches are being explored in 
order to slow down the progression of diabetes using antigen-specific and non-antigen-
specific immunotherapies. The most promising results could be based on the induction of 
specific immunotolerance, because of the harmful health effects that could be observed 
when non-antigen-specific drugs are used. 
Finally, it is possible that the etiological factors may be different from one patient to another 
and humoral immune response would be a relatively late marker for the disease 
progression. Most clinical trials have therefore been hampered by the lack of cellular 
markers of the immune processes that cause the disease. 
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